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PhosphataseInotropy and lusitropy in the ventricular myocyte can be efﬁciently induced by activation of β1-, but not β2-,
adrenoceptors (ARs). Compartmentation of β2-AR-derived cAMP-dependent signalling underlies this
functional discrepancy. Here we investigate the mechanism by which caveolae (specialised sarcolemmal
invaginations rich in cholesterol and caveolin-3) contribute to compartmentation in the adult rat ventricular
myocyte. Selective activation of β2-ARs (with zinterol/CGP20712A) produced little contractile response in
control cells but pronounced inotropic and lusitropic responses in cells treated with the cholesterol-depleting
agent methyl-β-cyclodextrin (MBCD). This was not linked to modulation of L-type Ca2+ current, but instead
to a discrete PKA-mediated phosphorylation of phospholamban at Ser16. Application of a cell-permeable
inhibitor of caveolin-3 scaffolding interactions mimicked the effect of MBCD on phosphorylated
phospholamban (pPLB) during β2-AR stimulation, consistent with MBCD acting via caveolae. Biosensor
experiments revealed β2-ARmobilisation of cAMP in PKA II signalling domains of intact cells only after MBCD
treatment, providing a real-time demonstration of cAMP freed from caveolar constraint. Other proteins have
roles in compartmentation, so the effects of phosphodiesterase (PDE), protein phosphatase (PP) and
phosphoinositide-3-kinase (PI3K) inhibitors on pPLB and contraction were compared in control and MBCD
treated cells. PP inhibition alone was conspicuous in showing robust de-compartmentation of β2-AR-derived
signalling in control cells and a comparatively diminutive effect after cholesterol depletion. Collating all
evidence, we promote the novel concept that caveolae limit β2-AR-cAMP signalling by providing a platform
that not only attenuates production of cAMP but also prevents inhibitory modulation of PPs at the
sarcoplasmic reticulum. This article is part of a Special Issue entitled “Local Signaling in Myocytes”.ARVM, adult rat ventricular
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In the cardiac myocyte, many receptors signal via the second
messenger cyclic AMP, but produce diverse changes in electrical,
mechanical, metabolic and transcriptional activities. This occursbecause different receptors produce changes in cAMP in different
compartments of the cell. The idea of cAMP compartmentation is well
accepted but the mechanisms responsible are not fully understood.
β1- and β2-adrenoceptors (AR), the predominant β-ARs in the
heart, provide an excellent illustration of compartmentalised cAMP
signalling in the adult ventricular myocyte. β1-AR stimulation
promotes positive inotropic and lusitropic responses, whereas β2-
AR stimulation has minimal functional effects [1,2]. These distinct
β-AR functional responses can be correlatedwith temporal and spatial
properties of cAMP generation [3], protein kinase A (PKA) activation
[4] and target protein phosphorylation [5]. In essence, β1-AR signals
are global, whereas β2-AR signals are localised to their site of
production. For example, β1-AR stimulation promotes PKA-depen-
dent phosphorylation of multiple targets throughout the cell — the L
type Ca2+ channel [6], phospholamban (PLB) [7], RyR [8] and
troponin I (TnI) [7]. By contrast, β2-AR signals do not access proteins
of the sarcoplasmic reticulum (SR) or myoﬁlaments [9,10].
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dependent signalling from the β2-AR.
Whilst the β1-AR couples to the stimulatory Gs protein, β2-ARs
couple sequentially to Gs and the inhibitory Gi protein. The Gi
pathway has been proposed as a key factor responsible for the spatial
restriction of β2-AR-cAMP signals to the sarcolemmal compartment,
perhaps through stimulation of protein phosphatase activity [11–13].
Another focus of interest is phosphodiesterase (PDE). Several studies
have suggested that PDE 3 and 4 contribute to the creation of the
distinct β2 AR cAMP signatures in the adult ventricular myocyte,
because PDE3/4 inhibition increases the size and duration of the cAMP
and activated PKA signals (e.g. [4,14]).
However, an additional, complementary, explanation for the
diverse effects of β1- and β2-AR stimulation on cAMP is that the
differential membrane distribution of signalling elements, including
receptors, produces cAMP signals in different cellular compartments.
The lipid bilayer is not a homogenous structure with randomly
distributed proteins, but contains liquid-ordered phases enriched in
cholesterol and sphingolipids known as lipid rafts. Caveolae are
specialised forms of invaginated rafts characterised by the presence of
caveolin and cavin proteins (see Refs. [15,16] for reviews). Caveolae
have been shown to be important structures for organising G-protein
coupled receptors and their downstream signalling components [17].
Within caveolae, oligomeric caveolin can assemble, and regulate,
macromolecular signalling complexes [18] through its ability to bind
many different proteins via its scaffolding domain [19].
In support of a role for caveolae in creating distinct β1- and β2-AR
cAMP signals, differential membrane distribution of receptors has
been reported in the ventricular myocyte. Whilst β1-ARs are found in
caveolar and non-caveolar domains, the majority of β2-ARs are
present exclusively in caveolae (in the absence of β AR stimulation)
[20–23]. Other elements of the β AR signal cascade (Gαs, Gαi,
adenylyl cyclase 5/6, PKA) have been shown to be present in caveolar
membrane fractions [20–23], to co-immunprecipitate with caveolin 3
[22] and to be inhibited by interaction with the caveolin scaffolding
domain [24–26]. The exclusive caveolar location of the β2-AR suggests
a role for caveolae in its downstream signalling. Indeed we have
recently shown functional evidence that caveolae compartmentalise
the β2 AR response in the adult ventricular myocyte; disruption of
caveolae reveals marked inotropic and lusitropic responses to β2-AR
stimulation [27], associated with a globalisation of cAMP-dependent
signalling indexed by phosphorylation of phospholamban [9].
The aim of the present study was to reconcile, for the ﬁrst time,
work showing the roles of phosphatases and phosphodiesterases in
spatial control of β2-AR signalling with mechanism(s) by which
caveolae compartmentalise cAMP in the adult ventricular cell. We
report how disruption of caveolae impacts on β2-AR signalling at the
level of cAMP, protein phosphorylation, ICa,L, [Ca2+]i and contraction,
and how this is affected by inhibition of key components linked with
β2-AR compartmentation. Measuring these different indices gives
insight into the mechanism of caveolar control (e.g. cAMP produc-
tion/cAMP degradation/phosphatase activity) and the region of the
cell (e.g. sarcolemma/SR/myoﬁlaments) in which this control oper-
ates. We show that spatial restriction of the β2-AR cAMP signal by
caveolae occurs at the level of cAMP production and phosphatase
activity in the SR. This can be explained by the formation of speciﬁc
signalling complexes in the caveolar microdomain.
2. Materials and methods
2.1. Cell isolation
Adult rat ventricular myocytes (ARVM) were enzymatically
isolated from the hearts of male Wistar rats using a standard
procedure outlined elsewhere [28]. Care was taken to follow the
Animals (Scientiﬁc Procedures) Act 1986, the Recommendation from theDeclaration of Helsinki and the Guiding Principles in the Care and Use of
Animals. All experiments were carried out at room temperature unless
otherwise stated and, except for those involving ﬂuorescence
resonance energy transfer (FRET), used ARVM on the day of isolation
in an extracellular buffer containing (mM): NaCl 137, KCl 5.4, MgCl2
0.5, CaCl2 1.0, NaH2PO4 0.33, glucose 5.5, HEPES 5 (pH 7.4).
2.2. Cell culture
For FRET imaging experiments only, ARVM were plated in
minimum essential medium (MEM) containing insulin–transferrin–
selenium complex (Invitrogen, CA, USA), bovine serum albumin
(1 mg/ml), 2,3-butanedione monoxime (10 mM) and penicillin–
streptomycin. After incubation for 2 h, the cells were transduced
with adenoviral constructs containing protein kinase A (PKA)- or
exchange protein activated by cAMP (Epac)-based cAMP biosensors,
as described previously [23,29,30]. Imaging experiments were carried
out 48–72 h after transduction.
2.3. β2-AR stimulation
Selective β2-AR stimulation was achieved with the β2 agonist
zinterol (ZNT, 10 μM) in combination with CGP20712A (CGP,
300 nM), a speciﬁc β1-AR antagonist. For all protocols, cells were
exposed to CGP for at least 5 min prior to addition of solution
containing ZNT and CGP. Baseline recordings were made in the
presence of CGP.
2.4. Methyl-β-cyclodextrin treatment
Freshly isolated ARVM were incubated for 1 h at 37 °C in Ca2+-
containing isolation solution (Ca-IS, [in mM]: NaCl 130, KCl 5.4, MgCl2
1.4, NaH2PO4 0.4, creatine 10, taurine 20, glucose 10, HEPES 5, (pH
7.4)) supplemented with 1–2 mM methyl-β-cyclodextrin (MBCD);
cultured cells were incubated under the same conditions with MBCD
dissolved in MEM-based culture medium. MBCD solution was
replaced with fresh solution and treated cells used within 3 h. We
have previously shown that incubation of myocytes with 1–2 mM
MBCD at 37 °C for 1 h removes cholesterol and Cav-3 from buoyant
caveolar membrane fractions [9] and markedly reduces caveolae
number [31].
2.5. TAT-tagged peptide treatment
Peptides corresponding to the 11-residue trans-activating tran-
scriptional activator sequence (TAT) from HIV-1, N-terminally linked
via 4 glycine residues to the 20-residue caveolin scaffolding domain of
Cav-3 (C3SD) or a scrambled version of this (Scram)were synthesised
(Peptide 2.0, VA, USA). Complete peptide sequences were: TAT-C3SD,
YGRKKRRQRRRGGGGDGVWRVSYTTFTVSKYWCYR; TAT-Scram,
YGRKKRRQRRRGGGGYWTVYTKVDFCGSRYVRTSW. Lyophilised stock
aliquots (0.5 mg) were reconstituted in water and diluted in Ca-IS.
ARVM were incubated in 0.5 or 1 μM peptide-Ca-IS solution at 37 °C
for 30 min. Peptide solutions ≥2 μM caused a marked decrease in the
viability of myocyte preparations.
2.6. Cell shortening and [Ca2+]i transient measurements
Unloaded shortening and [Ca2+]i transients were recorded
simultaneously using digital edge-detection software (IonOptix, MA,
USA) and an OptoScan monochromator (Cairn Research, UK) in ﬁeld-
stimulated ARVM (0.5 Hz) loaded with 1.5 μM fura-2, following
previously described protocols (Calaghan et al., 1998). An average of
10–12 traces under basal conditions, and at steady-state following
drug application, were analysed using IonWizard 6.0 software
(IonOptix).
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ICa,L was recorded as described in Agarwal et al. [23]. In brief,
experiments were performed using Cs+-based extracellular and
intracellular solutions in the whole-cell conﬁguration. Membrane
potential was stepped from−80 mV to−40 mV (50 ms) to inactivate
INa, followed by a 100 ms step to 0 mV to activate ICa,L. This protocol
was repeated at 5 s intervals.
2.8. FRET imaging
Experiments were performed using myocytes expressing PKA- or
Epac2-based sensors as described previously in detail [23,29,30].
Changes in cAMP levels were deﬁned as relative changes in the ratio of
the background and bleed-through corrected CFP and YFP (FRET)
ﬂuorescence intensity measured over the area of the entire cell.
2.9. Total and phospho-protein detection
Myocytepopulationsused tomeasurephospho-protein responses to
β2-AR stimulation were ﬁeld-stimulated (0.5 Hz) during drug treat-
ment, then immediately homogenised in immunoblot sample buffer
(ISB: 62.5 mM Tris [pH 6.8], 10% [v/v] glycerol, 2% [w/v] SDS, 1x protease
(Roche, Basel, Switzerland) and phosphatase (Thermo Fisher Scientiﬁc,
Northumberland, UK) inhibitor cocktails). Samples were immediately
frozen and stored at−20 °C until required; 5% (v/v) β-mercaptoethanol
wasaddedand samplesheated to95 °C for5 minbefore electrophoresis.
Proteins were separated by SDS-PAGE, transferred to PVDF membranes
and antibody steps were performed as described in Calaghan et al. [28].
Loading volumes were standardised to rod-shaped cell number,
depending on the target (5000 cells/well for total and phosphorylated
PLB; 30000 cells/well for total and phosphorylated TnI and RyR2).
Following enhanced chemiluminescence, only non-saturated signals
were quantiﬁed (Aida Image Analyzer).
2.10. Membrane fractionation
ARVM membrane populations were fractionated in a detergent-
free system using a discontinuous sucrose density gradient as recently
described [9]. Caveolae-containing fractions (5 and 6) were identiﬁed
on the basis of high buoyant density, enrichment in Cav-3 and
exclusion of β-adaptin.
2.11. Materials
All materials were purchased from Sigma-Aldrich (Dorset, UK)
unless otherwise stated. Zinterol hydrochloride was from Tocris
Bioscience (MO, USA) and EHNA (erythro-9-(2-hydroxy-3-nonyl)
adenine) hydrochloride was from Calbiochem (NJ, USA). Fura-2AM
was fromMolecular Probes. β2-AR, Gαi3, AC5/6, and GRK2 antibodies
were obtained from Santa Cruz Biotechnology (CA, USA). PLB, PLB
phospho-Ser16, RyR phospho-Ser2809 and RyR phospho-Ser2030 were
from Badrilla (West Yorkshire, UK) [32]. β-adaptin and monoclonal
Cav-3 antibodies were all from BD Transduction Laboratories (NJ,
USA). PP2A, TnI, and TnI phospho-Ser23/24 antisera, calyculin-A,
milrinone and rolipram were purchased from Cell Signaling Technol-
ogy (MA, USA). The PKA-RII antibody was from Millipore (MA, USA).
The PDE3A antibody was purchased from FabGennix (TX, USA). The
PDE4D antibody was a kind gift from Prof. Miles Houslay (University
of Glasgow, UK) [33,34].
2.12. Statistical analysis
All data are expressed as mean±S.E.M of n preparations.
Statistical signiﬁcance (Pb0.05) was determined by the Student's
t-test.3. Results
In the last decade, studies of the role of caveolae in cAMP signalling
in the ventricular myocyte have been conducted primarily in neonatal
cells [22,35–37]. However, this is not the perfect model of its adult
counterpart as developmental changes in cAMP compartmentation
occur in these cells [20]. Therefore from the outset our aim was to
conduct all our experiments in a single physiologically relevant
system, the adult ventricular myocyte.
We began by looking at the effect of disrupting caveolae withMBCD
on the functional response to β2-AR stimulation. We have previously
used a combination of the β2-AR agonist salbutamol and the β1-AR
antagonist atenolol to activate the β2-AR pathway in the ARVM. For the
present study, we chose the more selective β2-AR agonist zinterol [38],
in combinationwith CGP20712A, a speciﬁc β1-AR antagonist. As shown
in Figs. 1 (A–D), we saw no signiﬁcant change in shortening
(4.9±5.8%) or [Ca2+]i transient amplitude (2.2±3.1%) upon applica-
tion of ZNT in the presence of CGP in control myocytes. By contrast,
MBCD-treated ARVM showed a robust inotropic response to ZNT
application (70.2±9.7%) associated with a corresponding increase in
the amplitude of the [Ca2+]i transient (21.1±4.1%). A small positive
lusitropic response (5.4±1.3% decrease in time to half relaxation, t0.5
relax) and increase in rate of [Ca2+]i transient decay (5.0±1.9%
decrease in t0.5 decay) were seen with β2-AR stimulation in control
cells; this was markedly enhanced (Pb0.001) in MBCD-treated ARVMs
(to 13.3±1.3% decrease in t0.5 relax and 16.5±1.9% decrease in t0.5
decay)(Figs. 1E, F). Thus, β2-AR stimulation does not manifest
measurable inotropic responses in control ARVM but elicits robust
inotropic and lusitropic responses in ARVM depleted of cholesterol,
which are associated with corresponding changes in [Ca2+]i.
The effects of MBCD can be ascribed solely to its ability to
scavenge cholesterol (rather than any non-speciﬁc actions of such a
large oligosaccharide), as the inotropic and lusitropic responses to
β2-AR stimulation were attenuated (Pb0.001 and Pb0.01, respec-
tively) by conjugating 1 mM MBCD with cholesterol in a molar ratio
of 1:8 (Figs. 1G, H).
Recent studies have suggested that the cAMP signals generated by
β2-AR activation are small in magnitude and transient in nature [3,4].
It follows that only very proximal targets might be susceptible to β2-
AR derived PKA phosphorylation. The β2-AR and the L-type Ca2+
channel have been shown to be closely associated in caveolar
microdomains in the ARVM [22,39]. We therefore reasoned that ICa,L
was a likely candidate for the observed functional consequences of
MBCD treatment. However, as Fig. 2 shows, ZNT had no signiﬁcant
effect on ICa,L in either control or MBCD-treated ARVMs, although both
groups showed robust increases in current after application of the
adenylyl cyclase (AC) activator forskolin (FSK). These data suggest
that the β2-AR contractile effects emerging after cholesterol depletion
are not due to modulation of ICa,L.
Next we sought to describe the temporal and spatial characteris-
tics of the cAMP signal underlying the inotropic and lusitropic
response to β2-AR activation in cholesterol-depleted ARVM using
different FRET-based cAMP biosensors. Experiments using biosensors
necessitated the maintenance of cells in culture for 48–72 h. Although
we have previously reported a reduction in total cellular cholesterol in
ARVM cultured for 72 h, MBCD is still effective in reducing cellular
cholesterol in these cells [23]. Furthermore, we are conﬁdent that
culture does not result in a marked loss of caveolae at the cell surface
(suggesting that cholesterol may not be depleted speciﬁcally from
caveolar domains) (see Supplementary Fig. 1). We began by using an
engineered cAMP sensor based on an intact PKA holo-enzyme
containing only type II regulatory (RII) subunits. Through its RII-
based design, this sensor is localised to speciﬁc subcellular locations
via interactions with A-kinase anchoring proteins (AKAPs). These
locations include caveolar and non-caveolar sarcolemma and SR
membranes [35,40]. In control ARVM expressing the PKA-based
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Fig. 1. Cholesterol depletion uncovers marked β2-AR-induced inotropy and lusitropy in adult rat ventricular myocytes (ARVM). Representative myocyte shortening (A) and [Ca2+]i
transient (B) traces from individual control and MBCD-treated cells under basal conditions (300 nM CGP) and after β2-AR activation with 10 μM ZNT+300 nM CGP. Scale bars
represent 2% and 5% change from baseline (y-axes in A and B, respectively) and 200 ms (x-axes). Mean data show ZNT-mediated change (Δ) in shortening (C), [Ca2+]i transient
amplitude (D), time to half (t0.5) relaxation (E), time to half (t0.5) decay of [Ca2+]i transient (F) in control and MBCD-treated ARVM (n=12–20 cells from N3 animals; **Pb0.01,
***Pb0.001). ZNT-mediated change in shortening (G) and t0.5 relaxation (H) in MBCD- and MBCD/cholesterol complex-treated ARVM (n=11–13 cells from N3 animals; **Pb0.01,
***Pb0.001). All comparisons with Student's t-test.
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corresponding sample current traces (inset) under control conditions (300 nM CGP, a),
following exposure to 10 μM ZNT+300 nM CGP (b), and after exposure to 1 μM
forskolin (FSK, c) in a control cell (A) and MBCD-treated cell (B). C, average ZNT-
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MBCD-treatment had no effect on basal ICa,L density (−5.1±0.26 vs−5.7±0.31 pA/pF
in control and MBCD-treated ARVM respectively) as reported previously [27] (n=17;
PN0.05; Student's t-test).
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(PN0.05) in the FRET response from baseline (1.3±1.4%) (Fig. 3C),
although in 3/6 cells we saw a small transient response (as illustrated
in Fig. 3A). All cells showed a robust PKA-probe response to 1 μM
isoproterenol with 100 μM isobutyl-1-methylxanthine (IBMX). When
the same experiments were performedwithMBCD-treated ARVM, we
saw a signiﬁcant increase in the FRET response to ZNT (4.7±1.4%)
(Figs. 3B, C). In 7/13 cells this response was sustained during the
5 min ZNT exposure (as illustrated in Fig. 3B). We have therefore
detected, in real-time, a β2-AR mobilisation of cAMP in PKA-II
containing regions of the MBCD-treated ARVM that is not evident in
control cells. These data mirror the effects of MBCD on shortening and
[Ca2+]i transient amplitude responses to ZNT.
In subsequent experiments, we determined the effect of choles-
terol depletion on cAMP responses indexed with a different biosensor
engineered around the cAMP binding domain from type 2 exchange
protein activated by cAMP (Epac2). As this sensor lacks the normal
tethering sequence found in the full-length Epac2 protein, it accesses
the cytosolic compartment of the cardiac myocyte and reports cAMP
signals that are qualitatively distinct from those indexed by the PKA-
based sensor [30,41]. In control ARVM expressing the Epac2 probe,exposure to 10 μM ZNT yielded a 4.3±0.8% increase in FRET (Figs. 3D
and F). Although the β2-AR cAMP signal is considered to be localised
to its site of production, we are not alone in reporting β2-AR FRET
responses to cytosolic cAMP sensors in the adult ventricular cell [3].
An initial concern was that this might reﬂect ZNT-stimulation of the
β1-AR, however this is unlikely to be the case because of the lack of
effect of ZNT on ICa,L; we have recently shown that β1-AR stimulation
with isoproterenol (1 nM), which gives an Epac response equivalent
to that seen here with ZNT, increases ICa,L by 15% [23]. Importantly, the
Epac FRET response in ARVM treated with MBCD was identical
(4.2±0.5%) to that seen in control cells (Figs. 3E and F). Therefore,
differences in cAMP signals between control andMBCD-treated ARVM
reported by cAMP biosensors exist only in regions of the myocyte
where PKA-RII is found. Interestingly, these data mirror our recent
observations that β1-ARs show enhanced PKA-probe, but not Epac-
probe, responses following MBCD treatment [23]. A signiﬁcant
proportion of β1 ARs is in caveolae [21–23]. The speciﬁc effects of
MBCD on PKA probe responses to β1- and β2-AR stimulation suggest
that caveolar signalling complexes restrain cAMP production selec-
tively in PKA RII domains.
Given that PKA-RII is found in many different regions of the adult
cardiac myocyte, our next aim was to identify which cellular
compartments are accessed by the observed ZNT-mediated mobilisa-
tion of cAMP in MBCD-treated cells. We addressed this question by
measuring PKA-dependent phosphorylation of 3 distinct targets
following β2-AR stimulation. The SR protein PLB is found in non-
junctional SR and is phosphorylated by PKA at Ser16, a modiﬁcation
which relieves its inherent inhibition of SR Ca2+-ATPase, SERCA, and
thus promotes re-uptake of Ca2+[42]. The major SR Ca2+ release
channel in ARVM, RyR2, is found predominantly within junctional SR
and can be positively modulated by PKA phosphorylation at Ser2809
and Ser2030[43,44]. At the myoﬁlaments, PKA exerts a Ca2+ de-
sensitising effect via dual phosphorylation of TnI at Ser23 and Ser24
[45]. These three proteins can act as spatial references to map the
pattern of PKA phosphorylation. Representative immunoblots in
Fig. 4A show that application of 100 nM isoproterenol markedly
increases the phospho-antibody signal intensity for the 3 targets in
both control and MBCD-treated ARVM. However, for all targets, no
change in phosphorylation status was detected between basal and β2-
AR-stimulated conditions in control ARVM (PN0.05). This was not
surprising given the lack of effect of ZNT on the magnitude of [Ca2+]i
transients and shortening in these cells. By contrast, β2-AR activation
in cholesterol-depleted ARVM produced a marked increase in Ser16
phosphorylated PLB (pPLB), in agreement with the effects of MBCD on
[Ca2+]i transient amplitude and t0.5 decay described in Fig. 1. We
detected no increase in phosphorylation of TnI or RyR2 (at Ser2809) in
MBCD-treated cells. In the latter case this could be related to previous
reports of a high background phosphorylation at Ser2809 in the
absence of any cAMP-raising stimulus [46]. We therefore repeated
these experiments with an antibody against RyR phosphorylated at
Ser2030, but we were unable to detect a phospho-RyR signal in either
group of cells, even following treatment with 100 nM isoproterenol
(data not shown). From the results displayed in Fig. 4A, we surmise
that the emergence of β2-AR responsiveness after cholesterol
depletion is linked to a discrete pattern of PKA activity in a cellular
compartment that contains PLB.
Up to this point, cholesterol depletion was employed to disrupt
lipid rafts which include, but are not limited to, caveolae. In order to
determine whether observed effects of MBCD could be ascribed
speciﬁcally to effects on caveolae, we designed a cell-permeable
peptide (TAT-C3SD) which competes with endogenous C3SD for the
same intracellular binding partners [47,48]. A second peptide (TAT-
Scram), containing a scrambled sequence of C3SD was used as a
negative control. We addressed the question of whether TAT-C3SD
has any effect on β2-AR-mediated cAMP signalling in ARVM using
pPLB as an index of discrete PKA activity revealed byMBCD treatment.
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pPLB after β2-AR activation which is not signiﬁcantly different from
that seen under basal conditions (PN0.05). By contrast, myocytes
treated with TAT-C3SD peptide show a markedly enhanced β2-AR
pPLB signal relative to CGP background level (Pb0.01 vs. TAT-Scram;
Fig. 4B). We cannot compare the relative magnitude of MBCD and
C3SD peptide effects on ZNT-induced pPLB, as analysis of immuno-
blots in this way is, at best, semi-quantitative. However, the
qualitative difference between TAT-Scram and TAT-C3SD treated
ARVM in terms of β2-stimulated pPLB is pointedly reminiscent of the
difference observed between control andMBCD-treated ARVM shown
in Fig. 4A. This supports our claim that MBCD treatment exerts its
effects via selectively targeting caveolae.
Our next aim was to reconcile data showing a role for PDEs [14]
and protein phosphatases (PP) [12] in the compartmentation of
β2-AR signals with the mechanism by which caveolae exert their
control on this pathway. We were also interested in phosphoinositide
3-kinase (PI3K), which lies upstream of both PDE [49] and PP [12]activation, through scaffolding and kinase-dependent activity respec-
tively. The PDE family is of prime importance in the creation of
intracellular gradients of cAMP (see Ref. [50]). Nevertheless, the
dependence of PDEs on intact caveolae has never, to our knowledge,
been explored in cardiac cells, although a recent report in hepatocytes
suggests that Cav-1 stabilises PDE3B in caveolae [51]. Adult rat
cardiomyocytes express predominantly PDE 3 and 4 isoforms (PDE
3A, 4A,B,D), with low levels of PDE2 [14]. We therefore compared the
effect of selective inhibition of PDE 2, 3 and 4 on β2-AR signalling in
control and MBCD-treated ARVM. Our premise was that if caveolar
control was dependent on PDE activity, then MBCD treatment would
diminish the impact of PDE inhibition on the β2-AR response. The
level of pPLB was measured in ARVM pre-treated for 15 min with
EHNA, milrinone or rolipram (to inhibit PDE 2, 3 or 4 respectively)
plus CGP, and following subsequent stimulation with ZNT (using the
same regime as outlined for experiments in Fig. 4A). The effects of the
inhibitors on basal phosphorylation (i.e. in the presence of CGP alone)
in the 2 groups of cells are shown in Supplementary Fig. 2. There was
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between control and MBCD cells. Figs. 5 (C–E) show the effect of each
PDE inhibitor on the β2-AR pPLB response, i.e. the fold-change in pPLB
with inhibitor plus ZNT over ZNT alone. In control ARVM (i.e. cells
with intact caveolae), inhibition of PDE3 or PDE4, but not PDE2,
signiﬁcantly enhanced phosphorylation of PLB during ZNT application
(Pb0.05). There was no signiﬁcant difference in the effect of any
inhibitor of PDE on β2-AR stimulated pPLB between control and
MBCD-treated cells. These data suggest that PDE3 and 4 make a
signiﬁcant contribution to compartmentation of the β2-AR cAMP
signal in control cells, which is consistent with previous work
showing that PDE3/4 inhibition increases the size and duration of
the β2-AR cAMP and activated PKA signals (e.g.[4,14]). However, as
MBCD treatment did not diminish the effect of PDE inhibition on
β2-AR pPLB responses, cAMP compartmentation by PDE 3 or 4 at the
level of the SR cannot be reliant on intact caveolae/rafts.
Next, using the same approach, we tested the effect of inhibitors of
PP (calyculin-A, which inhibits PP1 and PP2A) and PI3K (LY294002)on the ZNT-induced phosphorylation status of PLB. In control
myocytes there was a trend for both calyculin-A and LY294002 to
enhance phosphorylation of PLB during β2-AR stimulation, but this
only attained signiﬁcance for calyculin-A (Pb0.05) (Figs. 5H, I). In
MBCD-treated myocytes, the effect of phosphatase inhibition was
signiﬁcantly reduced (Pb0.01) compared with control cells. We are
aware that effects of inhibitors on basal phosphorylation of PLB may
affect the response to β2-AR stimulation. However, this cannot
account for the reduced effect of calyculin-A in MBCD cells as basal
phosphorylation was not different in MBCD cells treated with this
drug compared with controls (Supplementary Fig. 2). The fact that
calyculin-A enhances β2-AR pPLB responses in control cells and that
its effects are diminished by MBCD implies a common pathway for
caveolar- and phosphatase-compartmentation of the β2-AR signal.
Together these data suggest that phosphatases make a major
contribution to compartmentation of β2-AR cAMP signalling, and
that this mechanism is dependent on intact caveolae.
To complement data shown in Fig. 5, we looked next at the effects
of inhibiting PDEs, PP and PI3K on control and MBCD-treated myocyte
function, which effectively indexes the sum of all phosphorylation
events in the cell. Inhibitors were applied after the response to ZNT
had stabilised (or after 5 min in the case of control cells yielding no
response), as illustrated in representative traces (Figs. 6A, B). The
impact of the isoform-speciﬁc PDE inhibitors on the steady-state β2
AR response is shown in Figs. 6 (C–J). In control cells, inhibition of
PDE2 with EHNA had no signiﬁcant effect (PN0.05 vs. 0) on
shortening or [Ca2+]i transient amplitude responses to β2-AR
stimulation (Figs. 6C, E), but slightly enhanced (Pb0.05 vs. 0) effects
of β2-AR stimulation on relaxation and decay kinetics (Figs. 6D, F).
The effect of EHNA was identical in MBCD-treated AVRMs. The PDE3
inhibitor milrinone signiﬁcantly enhanced (Pb0.05 vs. 0) ZNT-
induced changes in shortening, [Ca2+]i transient amplitude, t0.5
relaxation and t0.5 decay in control cells; quantitatively similar effects
were seen in MBCD-treated ARVM (PN0.05 between groups). The
identical effects of PDE2 or 3 inhibition in control vs MBCD cells
suggest that PDE2/3 inhibition and MBCD exert independent in-
ﬂuences on β2-AR-stimulated cell function. The same comparison
between control and MBCD-treated cells was not possible with PDE4
inhibition as application of rolipram (200 nM – 1 μM) elicited
spontaneous contractile events in MBCD cells (see Supplemental Fig.
3), indicating a level of Ca2± dysregulation that precluded analysis of
electrically evoked [Ca2±]i transients. These synergistic effects of
cholesterol depletion and PDE4 inhibition warrant further investiga-
tion. However, for the purpose of the present study, these data suggest
that the functional effects of rolipram are not attenuated in MBCD cells
vs controls, as we report for pPLB.
Figs. 7 (A–D) show the impact of inhibition of PP on functional
responses to β2-AR stimulation in control and MBCD-treated ARVMs.
Exposure of control ARVM to calyculin-A markedly enhanced ZNT-
stimulated cell shortening and [Ca2+]i transient amplitude (by
134±22 and 28.2±5.1% respectively), and further decreased t0.5
relaxation and t0.5 transient decay (by 11.3±4.9 and 15.7±2.2%
respectively). The effects of calyculin-A on shortening and [Ca2+]i
transient amplitude were signiﬁcantly attenuated (Pb0.05) in MBCD
cells compared with controls (to 51.9±15.4% and 10.8±4.4%
respectively)(Figs. 7A, C). Furthermore, calyculin-A reversed the
positive lusitropic effect of β2-AR stimulation in MBCD-treated ARVM
(18.0±5.7% increase in t0.5 relaxation) (Fig. 7B), but this was not
associated with a corresponding change in [Ca2+]i transient decay
(Fig. 7D). The attenuation of calyculin-A effects on β2-AR responses in
MBCD cells vs. controls conﬁrms a caveolae-dependent role for PP in
limiting β2-AR signals. Although we failed to detect a difference in the
effect of calyculin A on t0.5 transient decay between control and MBCD
AVRM, we are reluctant to interpret this as evidence that caveolar
phosphatases are not active in the PLB compartment, given that
calyculin-A has signiﬁcantly less effect on phospho-PLB in MBCD cells
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because t0.5 transient decay indexes more than SR Ca2+ uptake control
by PLB; it is a composite of many mechanisms that alter [Ca2+]i,
including SR Ca2+ uptake, SR Ca2+ leak and sarcolemmal Ca2+
extrusion.
The effect of PI3K inhibition on functional responses to β2-AR
stimulation is shown in Figs. 7 (E–H). In control cells, the application
of LY294002 signiﬁcantly enhanced (Pb0.05 vs. 0) cell shortening,
[Ca2+]i transient magnitude, the rate of relaxation and the rate of
transient decay in response to ZNT. None of the LY294002-induced
changes in cell shortening and [Ca2+]i transient parameters was
signiﬁcantly different between control and MBCD-treated groups
(PN0.05 for all comparisons), suggesting that PI3K control of the β2
AR signal is not dependent on caveolae.
Together these functional data suggest that PDE3, PI3K and
phosphatases make a signiﬁcant contribution to compartmentation
of β2 cAMP signalling in the control AVRM, which is in agreement
with previous reports [12,14]. We were unable to conﬁrm a
contribution from PDE4 seen in experiments using pPLB as our
index of the cAMP signal because of dysregulation of [Ca2+]i when
PDE4 was inhibited in MBCD-treated cells. Comparison of datasetsusing pPLB and cell function as indices of cAMP signals demonstrates
that we were only able to detect a signiﬁcant contribution from PI3K
to restriction of the β2-AR cAMP signal using functional endpoints.
The disparity between these results may reﬂect the fact that PI3K
effects are not mediated through changes in a cAMP compartment
that contains PLB. However, an alternative explanation is that the
statistical power of our functional experiments is higher because we
were able to measure the effect of ZNT alone and ZNT plus inhibitor in
the same cell.
According to our premise that if a particular regulatory element
were dependent on intact caveolae, the effect of inhibition of this
element would be reduced in MBCD-treated cells, these data identify,
for the ﬁrst time, phosphatases as caveolae-dependent factors which
compartmentalise β2-AR signalling.
Although caveolar-dependent phosphatases contribute to com-
partmentalisation of β2-AR signalling in the ventricular cell, this
cannot be the only mechanism by which caveolae act in this regard
because, as shown using FRET-based biosensors, disruption of
caveolae with MBCD also increases cAMP levels in a PKA RII
compartment. The level of cAMP in the cell will represent a balance
between cAMP production (by AC) and degradation (by PDEs). Our
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of cAMP through effects on PDE activity, therefore we conclude that
caveolae must regulate cAMP production by AC. β2-ARs couple
sequentially to Gs and Gi proteins [52]. β2-AR cAMP generation can be
modulated through changes in Gαs and Gαi coupling (which
respectively activate and inhibit AC 5/6) [53] and through receptor
internalisation (which curtails cAMP production) [54]. A common
mechanism which controls both β2-AR-G protein coupling and
internalisation is receptor phosphorylation. Receptors can be phos-
phorylated by PKA [55] and G protein receptor kinase (GRK [56]). PKA
and GRK phosphorylation of the β2-AR shifts coupling from Gs to Gi
[55,57] and GRK-dependent phosphorylation recruits β-arrestin to
the receptor [58,59] which prevents receptor-G protein coupling and
triggers receptor internalisation. One attractive model for caveolar
restriction of β2-AR cAMP production is that the caveolar compart-
ment facilitates PKA- and/or GRK-dependent phosphorylation of the
receptor. Therefore, in order to gain insight into how caveolae control
cAMP production and phosphatase activity, we performed sucrose
gradient fractionation to look at the distribution of relevant signal
components between caveolar and non-caveolar domains in control
cells. As shown in Fig. 8, the buoyant Cav-3 containing fractions (5 and
6) contain the majority of the β2-AR and AC 5/6, a signiﬁcant
proportion of Gαi, PKA RII and PP2A, and aminor component of GRK2.
The main PDE3 and 4 isoforms expressed in the rat heart, PDE3A andPDE4D, were found almost exclusively in non-caveolar fractions. This
membrane distribution of key components of the β2-AR pathway
provides a potential framework for caveolar control of cAMP
production by facilitating PKA/GRK2 phosphorylation of the β2-AR
and consequent receptor-Gi coupling. This, in turn, could have
consequences for regulation of phosphatases in the SR compartment
(see Discussion).
4. Discussion
Compartmentation of cAMP is a fundamental strategy which allows
cells to orchestrate complex receptor signalling with a single second
messenger. Over the last decade a body of evidence has accumulated
which suggests that Gi coupling, protein phosphatases and PDEs play
essential roles in creating the distinct β2-AR cAMP-dependent signature
in the ventricular myocyte. At the same time, a number of groups,
including our own, have shown that compartmentation of the β2-AR
pathway is dependent on the caveolar microdomain.
Here, for the ﬁrst time, we reconcile these data by showing how
the spatial characteristics of the cAMP signal and PKA-dependent
phosphorylation following β2-AR stimulation are dependent on
caveolae, and how PDEs, PP and PI3K contribute to caveolar control.
The 2 essential aspects of our experimental design were to use the
most physiologically relevant model (adult ventricular myocytes
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the β2-AR (through use of the β2-AR agonist ZNT with a selective β1
antagonist CGP). As we predicted our approach has revealed
discrepancies with other studies using neonatal myocytes and
and/or other drugs to activate the β2-AR.
In the present study, control ARVM showed no change in shortening,
[Ca2+]i transient amplitude or ICa,L in response to β2-AR stimulation
with 10 μM ZNT in the presence of 300 nM CGP. This is consistent with
other work in these cells using this combination of ZNT and CGP [1,60].
We show here that disruption of caveolae through cholesterol depletion
withMBCD allows β2-AR stimulationwith ZNT to elicit robust inotropic
and lusitropic responses which can be ascribed to effects on SR Ca2+
uptake and/or release, with no contribution from ICa,L .
These data contrast with our previous work showing a small ICa,L
response to β2-AR stimulation with the β2-AR agonist salbutamol
(with atenolol) in control cells that is potentiated by MBCD treatment
[27]. The difference between the effects of zinterol and salbutamol
could arise because of ligand-selective agonism, whereby down-
stream Gs/Gi coupling is determined by a particular ligand's
stereochemical properties [61,62]. However, in the context of our
recent report that MBCD treatment can potentiate the ICa,L response to
sub-maximal β1-AR stimulation [23], a more likely explanation is that
salbutamol (with atenolol) produces a small, but signiﬁcant, activa-
tion of the β1-AR pathway.
A key question for the present studywas how the functional effects
of β2-AR stimulation with zinterol in MBCD-treated cells relate to
changes in the spatial characteristics of the cAMP signal and the
resulting PKA-dependent phosphorylation. Both PDE and PP have
been linked with control of the β2-AR signal, and compartmentation
may occur at the level of cAMP and protein phosphorylation
independently. We used FRET-based biosensors that allow measure-
ment of cAMP in real-time in 2 different cellular compartments to
show that disruption of caveolae with MBCD reveals a nascent β2-AR
stimulated rise in cAMP speciﬁcally in PKA-RII regions of the cell. This
rise in cAMP in a PKA-RII compartment is associated with a selective
increase in phosphorylation of the SR protein PLB, which suggests thatthe increase in cAMP occurs speciﬁcally in the PLB-containing
compartment of the SR. Indeed, this accords with the fact that
MBCD enhances the rate of [Ca2+]i transient decay in response to β2-
AR stimulation. However, at this stage we cannot exclude the
possibility that changes in PP activity could also contribute to altered
phosphorylation of PLB.
Again, these experiments highlight subtle differences in the
subcellular effects of different β2-AR agonist/β1-AR antagonist pairs.
In the present study, of our 3 PKA targets selected as spatial reference
points in the cell (PLB, RyR and TnI), only PLB was phosphorylated by
β2-AR in MBCD-treated cells. However, with salbutamol (plus
atenolol), β2 stimulation also enhances TnI phosphorylation in MBCD
treated cells [9]. Again, a simple explanation is that this represents
effects mediated through stimulation of a β1-AR component.
We have shown that the cholesterol-depleting agent MBCD
markedly reduces caveolar density [31], but this does not guarantee
that MBCD effects on the β2-AR pathway are mediated through
caveolae, as cholesterol is also enriched in non-caveolar lipid rafts, and
additionally contributes to physical properties (thickness, ﬂuidity) of
non-raft membranes [63]. However, here we show that a cell
permeable peptide, which severs the interaction of Cav-3 with its
normal binding partners, mimics the effect of MBCD on phosphoryla-
tion of PLB following β2 stimulation. Thus we are conﬁdent that the
MBCD effects we report are mediated through the caveolar
microdomain.
Having established phosphorylation of PLB as a robust index of the
β2-AR signal seen when caveolae are manipulated by MBCD or TAT-
C3SD, we were able to test how the various components linked with
compartmentalisation of this pathway are involved in caveolar
control. These data show that, whilst PDE3, PDE4 and PP contribute
to compartmentation of the β2-AR signal in control cells, only the PP
effect is dependent on caveolae. When we take changes in [Ca2+]i and
contractility together as an index of the sum of all phosphorylation
events occurring following β2-AR stimulation, we see an additional
contribution from PI3K in control cells, but the pattern of response to
all inhibitors between control and MBCD-treated cells is maintained.
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signal by PDEs is independent of caveolae, whilst control by PP is
dependent on an intact caveolar domain.
Data from effects of calyculin-A (Figs. 5 and 7), and measurement
of cAMP biosensor responses (Fig. 3), strongly support the view that
caveolae exert their compartmentalisation of β2-AR signals through
effects on both cAMP production and phosphatase activity. With
regard to the former effect, we were particularly interested in the
possibility that this could be regulated via phosphorylation of the β2-
AR by either PKA or GRK. Receptor phosphorylation has been shown
to affect the kinetic characteristics of the β2-AR signal [64] and it has
been suggested recently that it is the transient nature of the β2-AR-
dependent cAMP signal that determines its spatial properties (e.g.
lack of propagation to the SR) [4]. Our PKA-probe data hint at this
change from transient to sustained cAMP signals when caveolae are
disrupted withMBCD (Figs. 3A, B). Wewere unable to measure β2-AR
phosphorylation directly, as antibodies for the PKA- and GRK-
phosphorylated receptors are raised against human β2-AR and do
not recognise the rat β2-AR expressed at endogenous levels (data not
shown). Instead we looked at the distribution of relevant components
between caveolar and non-caveolar membrane fractions. As others
have reported previously in the adult myocyte, we see the majority of
β2-AR and AC 5/6 in caveolae-containing fractions, along with a
signiﬁcant proportion of Gαi and PKA RII [20,22]. GRK2, thepredominant cardiac isoform [65], was found mostly in non-caveolar
fractions, with only a small component in caveolar rafts, as has been
reported previously in neonatal cells [35]. This observed pattern of
membrane distribution of components could facilitate PKA- (and
perhaps GRK2-) dependent phosphorylation of the β2-AR and
thereby coupling between β2 and Gi. Indeed we have previously
shown that abolition of Gi signalling with pertussis toxin mimics the
effect of MBCD on the inotropic response to β2-AR stimulation [27],
suggesting that caveolae control is exerted through Gi.
The demonstrated role for phosphatases in the compartmentation
of the β2-AR response could be linked with caveolae as a β2-Gi
compartment described above. In the ARVM, pertussis toxin enhances
phosphorylation of PLB induced by zinterol [12] and has equivalent
non-additive effects to calyculin-A on β2-AR mediated inotropy [11].
This suggests that PP activation is Gi-dependent. PP2a is found
predominantly at the sarcolemma [66], where a proportion is present
in caveolae (as we show here) in a complexwith Cav-3 [22]. However,
our data suggest that the role of caveolae in phosphatase-dependent
restriction of β2-AR signalling is exerted at the level of SR (PLB).
Interestingly, a signiﬁcant proportion of PP1, which is also inhibited
by calyculin-A, is found in SR membranes [66]. PP1 is under the
control of PP inhibitor 1 (I-1) [67] and PKA-dependent phosphory-
lation of I-1 enhances its inhibitory effect on PP1, keeping PP activity
low [68]. We speculate that disrupting caveolae enhances cAMP
production (by effects on Gi-β2-AR coupling); this in turn engenders a
more sustained (and propagating) activation of PKA which increases
phosphorylation of PLB both directly, and by dampening PP1 activity
via I-1. It is interesting to note that PP1 isoforms are differentially
distributed in longitudinal SR and junctional SR [66] which could
account for the differential effects of disrupting caveolae on
phosphorylation of PLB and RyR that our data suggest. This model of
compartmentation by caveolae is represented schematically in
Supplementary Fig. 4.
5. Conclusions
The present study has shown for the ﬁrst time that caveolae
compartmentalise the β2-AR pathway through effects on cAMP
production and phosphatase activity, which can be ascribed to
facilitation of receptor-Gi coupling. Although the β2-AR pathway may
contribute little to the contractile effects of sympathetic stimulation in
the healthy heart, it is likely to play a signiﬁcant role (through
modulation of β1 responsiveness [69], and anti-apoptotic signalling
[70]) in heart failure. Insight into the caveolar control of β2-AR
signalling will impact on our understanding of changes that take place
in the failing heart, given that heart failure is associated with increased
β2/β1-AR ratio [71], higher Gi expression [72] and diverse changes in
caveolae [73–75].
Supplementarymaterials related to this article can be found online
at doi:10.1016/j.yjmcc.2011.06.014.
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